Pharmaceutical industry leaders are increasingly focused on infectious diseases amid the COVID-19 pandemic and growing concern over treatment-resistant superbugs. In July, a group of drugmakers including Pfizer announced they raised almost $1 billion for a partnership promising to deliver two to four new antibiotics by 2030.
Apart from vaccines, Pfizer’s anti-infective pipeline was thin before the Amplyx acquisition, with a treatment for COVID-19 in Phase 1 studies and an antibiotic in Phase 3. But the company’s head of hospital products, Angela Lukin, said Wednesday that Pfizer is “deeply committed” to its infectious disease program.
Fosmanogepix could prove to be a weapon against fungal infections because of its mechanism of action, Pfizer said. The Food and Drug Administration hasn’t approved a new class of antifungal therapies in almost 20 years. Researchers are currently studying both oral and intravenous forms of the drug, which in theory would help patients transition from the hospital to home. READ MORE
By Kristin Jensen
Source: biopharmadive.com
AbbVie will be among the stocks closing out a busy earnings week. Earnings season tends to draw a lot of interest from investors, but it’s not always the best indicator of a stock’s overall trajectory.
Surgical Theater’s technology builds 3D models of an individual patient’s anatomy from CT and MRI scans to offer surgeons an immersive, 360-degree fly-through view.
The self-styled gene therapy “development engine” raised $120 million to quickly expand capacity for its adeno-associated virus (AAV) contract manufacturing services—and triple its workforce along the way.
